Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ: ATAI )

2.040 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
27 28 Next >
Psyched Wellness is The First Public Company To Bring Amanita Muscaria For Human Consumption To The U.S.
Easily identified by its red cap covered with white dots and a white stem, the Amanita muscaria mushroom is probably the most famous and easily recognizable mushroom in the world. Popularized by Lewis... 
Via Benzinga
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: 
Via Benzinga
Why Shares of atai Life Sciences Climbed 14.58% on Tuesday
The company specializes in developing psychedelics as therapies. 
Via The Motley Fool
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
From atai Life Sciences
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads. 
Via Benzinga
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
From atai Life Sciences
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo's Investment Fundamentals & Specificities
(Part one of a four-part series) 
Via Benzinga
A Sinister Reason May Be Behind Governors' Opposition To Cannabis Legalization
As one Republican governor after another rejects President Biden’s suggestion to pardon simple cannabis possession convictions, one wonders what they're thinking. 
Via Benzinga
October Recap: Major Psychedelic Drug Stocks Declined 9.9%
In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD. 
Via Talk Markets
Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87 
Via Benzinga
Atai's Phase 2 Study For Treatment-Resistant Depression Completes Enrollment, Expects Results Soon
Clinical stage psychedelics company atai Life Sciences (NASDAQ: ATAI) and its majority-owned subsidiary Perception Neuroscience completed patient enrollment for their Phase 2a clinical trial assessing... 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 25, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39 
Via Benzinga
Canadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA Track
Drug delivery company IntelGenx Corp. 
Via Benzinga
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week
The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since... 
Via Talk Markets
Allied, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53 
Via Benzinga
atai Life Sciences Announces R&D Day Agenda
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From October 18, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 78 companies made new 52-week lows. 
Via Benzinga
Atai Launches Phase 1 Clinical Trial On Novel Direct-To-Brain Drug Delivery Technology
Clinical stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient ( 
Via Benzinga
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From October 17, 2022
GAINERS: Biomind Labs (OTC:BMNDF) shares closed up 38.18% at $1.52 
Via Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 12, 2022
GAINERS: Allied (OTC:ALID) shares closed up 48.05% at $0.48 
Via Benzinga
Novel Psychedelic Compound Show Positive Results For Opioid Use Disorder Treatment
Kratom grows in several Asian countries and has been traditionally used by local communities as a natural home remedy for pain, depression and addiction. 
Via Benzinga
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.